(Q38325814)

2 September 2017

1 reference

title

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease (English)

1 reference

2 September 2017

Zhong-Min Liu

1

1 reference

2 September 2017

Miao Hu

series ordinal

2

1 reference

2 September 2017

Paul Chan

series ordinal

3

1 reference

2 September 2017

Brian Tomlinson

series ordinal

4

1 reference

2 September 2017

language of work or name

English

0 references

publication date

21 January 2015

1 reference

Expert Opinion on Investigational Drugs

2 September 2017

published in

1 reference

2 September 2017

volume

24

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

611-621

1 reference

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Evolving therapies for non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The safety of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Novel peroxisome proliferator activated receptor-alpha agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Lipoproteins and coronary heart disease in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Withdrawal of cerivastatin from the world market

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Lipid lowering with PCSK9 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Bezafibrate Improves Hypertension and Insulin Sensitivity in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

Stemming the global tsunami of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1006359

10.1517/13543784.2015.1006359

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference